Isomorphic Labs Limited is a London-based drug discovery company, which uses artificial intelligence for drug discovery.  Isomorphic Labs was founded by Demis Hassabis. The company was incorporated on February 4, 2021 and announced on November 5, 2021. It was established under Alphabet Inc. as a spin-off from its AI research lab DeepMind. Hassabis is the CEO and founder.
The company draws upon DeepMind's AlphaFold 2 technology, which can be used to predict protein structures in the human body with high accuracy, allowing its researchers to find new target pathways for drug delivery.
In December 2022, Isomorphic Labs announced its second office location in Lausanne, Switzerland.
In January 2024, Isomorphic Labs partnered with Novartis AG and Eli Lilly & Company to work together on AI drug discovery and research.